#United States #Indianapolis #Zepbound #Eli Lilly #Mounjaro

Eli Lilly's Impressive Q3 2026 Financial Performance

Eli Lilly and Company has announced remarkable financial results for the third quarter of 2026, reflecting a notable 39% increase in revenue, which soared to $24.4 billion, largely driven by its key products Mounjaro and Zepbound. This increase is underscored by a substantial benefit of approximately $900 million from various factors, including substantial milestones related to the jardinance product line.

Enhanced Earnings Performance

Further, the company's earnings per share (EPS) also saw a significant increase of 16%, reaching $7.22 on a reported basis. Adjusted non-GAAP EPS climbed by 7% to $7.48, despite incurring $4.57 in acquired in-process research and development (IPRD) charges, compared to only $0.71 in the same quarter last year. These figures are a testament to the company’s robust financial health and operational efficiency in a highly competitive environment.

Updated Guidance for 2026

In light of its stellar performance thus far, Eli Lilly revised its full-year guidance, elevating the midpoint of its revenue forecast by $5.5 billion, setting the new range between $91.0 and $92.0 billion. Significantly, the company increased its underlying non-GAAP EPS guidance by $4.07, navigating through the complexities of recent IPRD charges from business development activities. This optimistic outlook is built on the steady demand for its products as well as a solid portfolio of ongoing clinical trials and regulatory approvals.

Regulatory Achievements and Product Pipeline

During this quarter, Eli Lilly reported several key regulatory advancements, most notably receiving approvals from the U.S. Food and Drug Administration (FDA) for Mounjaro, aimed at reducing cardiovascular risk in type 2 diabetes patients. Additionally, they launched Onswik, a weekly basal insulin product, and received expanded indications for Inluriyo and Jaypirca, enhancing treatment options in oncology and endocrinology.

The company highlighted promising results from its pipeline, including a head-to-head Phase 3 trial between retatrutide and Ozempic, showing superior performance regarding A1C reduction and weight loss. Furthermore, Phase 3 findings from Ebglyss on treating moderate-to-severe hand and foot atopic dermatitis exhibited positive outcomes, and Phase 2 results for EloraTZP in obesity and type 2 diabetes showed encouraging progress.

Commitment to Innovation and Growth

Lilly's growth strategy is bolstered by key acquisitions in the mental health domain, including AtaiBeckley, and a recent deal to acquire Merida Biosciences targeting severe autoimmune disorders. The firm emphasized an unwavering commitment to innovation, announcing expansions in manufacturing capabilities in Texas and Virginia to support the growing demand for its drug portfolio.

According to David A. Ricks, chair and CEO of Eli Lilly, the company is focused on executing its vision of enhancing public health through cutting-edge treatments. Lilly's approach of investing in advanced technologies and partnership initiatives is aimed at addressing significant health challenges while driving lasting growth.

Financial Highlights Overview

Here’s a brief overview of Eli Lilly’s financial results for Q3 2026:

• - Revenue: $24.4 billion (39% increase from Q3 2025)
• - Net Income: $6.5 billion (16% increase)
• - EPS (Reported): $7.22
• - EPS (Non-GAAP): $7.48
• - Key Products Revenue: $17.1 billion, featuring significant growth for Mounjaro and Zepbound

Overall, Eli Lilly’s third-quarter results reflect a strategic combination of strong sales performance, regulatory success, and a proactive approach to business development, showcasing its resilience and potential in the ever-evolving pharmaceutical landscape.

As Eli Lilly moves forward, stakeholders anticipate continued innovation and growth, sustaining the company’s mission of making life better for millions globally.